Contact Us

YAZ Side Effects
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



Date of Birth of Person Using Yaz, Yasmin, or Ocella

Date Started Using Yaz, Yasmin, or Ocella

Date Stopped Using Yaz, Yasmin, or Ocella

Date-of-Injury : 

Did you experience any of the following complications during or after using Yaz, Yasmin, or Ocella

What injury have you suffered?

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Mediation Bid Postpones First Yaz, Yasmin Lawsuit Trial

Jan 5, 2012 | Parker Waichman LLP

The much anticipated first bellwether trial in the Yaz and Yasmin multidistrict litigation won't be starting next week after all.  The trial was postponed, and U.S. District Court Judge David Herndon has ordered both sides to meet with a mediator to discuss possible settlement of Yaz and Yasmin lawsuits.

George Washington law professor Stephen Saltzburg has been appointed special master in the litigation. In an order dated December 31, Judge Herndon directed attorneys for both plaintiffs and defendants to meet with Saltzburg “without delay” to negotiate in good faith. According to FiercePharma, Saltzburg previously handled mediation for more than 20,000 Seroquel product liability lawsuits.

More than 10,000 lawsuits are pending before Judge Herndon in the Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100) in the U.S. District Court for the Southern District of Illinois. The lawsuits claim Yaz, Yasmin and similar drugs caused young women to suffer dangerous blood clots and other serious side effects.

Just last month, a panel of advisors for the U.S. Food & Drug Administration (FDA) recommended stronger label warnings for Yaz, Yasmin and similar oral contraceptives regarding their possible association with blood clots.  The outside advisors voted 21-5 that current label warnings for Yaz, Yasmin and other pills made with the progestin, drospirenone, are inadequate and need to include clearer information about data that have linked the pills to a higher risk of blood clot

Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo